Alto Neuroscience, Inc. announced multiple presentations at the 63rd annual meeting of the American College of Neuropsychopharmacology, highlighting progress across its pipeline and precision psychiatry platform. New preclinical data demonstrated a direct link between the mechanism of ALTO-300 and the electroencephalogram (EEG) biomarker used for patient selection.
The data showed that ALTO-300, which blocks the 5-HT2C serotonin receptor and increases dopamine release, correlates with a measure of reduced neural signal stability captured by its EEG biomarker. This insight enhances the understanding of the patient phenotype being studied in the ongoing Phase 2b trial and provides mechanistic relevance to the machine-learning derived biomarker.
The company also announced plans to conduct an interim analysis for the ongoing Phase 2b trial of ALTO-300 as an adjunctive treatment in Major Depressive Disorder. This analysis, expected in the first quarter of 2025, will inform the final sample size needed to achieve adequate powering for the trial, with topline data from the complete study sample anticipated in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.